46,780 Shares in Masimo Co. (NASDAQ:MASI) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in shares of Masimo Co. (NASDAQ:MASI) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 46,780 shares of the medical equipment provider’s stock, valued at approximately $7,733,000. Proficio Capital Partners LLC owned 0.09% of Masimo at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the 4th quarter worth about $27,000. UMB Bank n.a. boosted its position in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont acquired a new position in shares of Masimo during the fourth quarter worth about $33,000. Blue Trust Inc. raised its holdings in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares during the period. Finally, Smartleaf Asset Management LLC lifted its position in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 60 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Stock Up 1.5 %

MASI opened at $168.21 on Friday. The stock’s fifty day moving average is $174.84 and its 200-day moving average is $157.65. The company has a market capitalization of $9.07 billion, a PE ratio of 116.01 and a beta of 1.03. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. On average, equities analysts predict that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MASI. Wells Fargo & Company upped their target price on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Piper Sandler increased their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.